MedPath

Postoperative Pain Management After Minimally Invasive Esophagectomy

Phase 4
Conditions
Esophageal Cancer
Registration Number
NCT02042313
Lead Sponsor
Sun Yat-sen University
Brief Summary

Esophagectomy is a major surgical procedure often associated with significant morbidity and mortality and significant level of postoperative pain. In contrast to open esophagectomy where epidural pain control has been considered as a gold standard and could be crucial in affecting outcome the analgesic scheme for minimally invasive esophagectomy (MIE) is yet to be established. We would like to compare continuous epidural analgesia and continuous paravertebral block combined with single shot subcostal transversus abdominis plane (TAP) block in the analgesic effects, levels of cytokines, and postoperative complications in patients receiving MIE.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
58
Inclusion Criteria
  • Patient has a physical status between ASA I and III
  • 20 - 75 years of age
  • Patient has signed an informed consent
  • Without contraindication of GA, EA or PVB
Exclusion Criteria
  • ASA > III
  • Inability to provide informed consent
  • Bleeding disorders
  • Being pregnant
  • Contraindications to nonsteroidal anti-inflammatory drugs (NSAIDs),
  • Allergy to amide-type local anesthetics or NSAIDs
  • Infection at the thoracic paravertebral injection site
  • Severe spine or chest wall deformity
  • Patients with major psychosis or drug and alcohol abuse
  • Patients with a history of significant neurological, psychiatric, neuromuscular, cardiovascular, pulmonary, renal or hepatic disease
  • Patients with physical disability that precludes complete cooperation

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Intraoperative hypotension ( > 30% decline in the preoperative systolic/diastolic blood pressure)during operation
Secondary Outcome Measures
NameTimeMethod
NRS pain scorepostoperative day 0 to 4

Trial Locations

Locations (1)

Koo Foundation Sun Yat-Sen Cancer Center

🇨🇳

Taipei, Taiwan

Koo Foundation Sun Yat-Sen Cancer Center
🇨🇳Taipei, Taiwan
Nai Liang Li
Contact
886-2-28970011

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.